October 1996
Volume 37, Issue 11
Free
Articles  |   October 1996
Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
Author Affiliations
  • A S Berger
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • C K Cheng
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • P A Pearson
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • P Ashton
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • P A Crooks
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • T Cynkowski
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • G Cynkowska
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • G J Jaffe
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
Investigative Ophthalmology & Visual Science October 1996, Vol.37, 2318-2325. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A S Berger, C K Cheng, P A Pearson, P Ashton, P A Crooks, T Cynkowski, G Cynkowska, G J Jaffe; Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.. Invest. Ophthalmol. Vis. Sci. 1996;37(11):2318-2325.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: Proliferative vitreoretinopathy (PVR) remains the most common cause of failed retinal detachment (RD) surgery. The authors compared the effectiveness of two intraocular sustained-release codrugs in suppressing PVR in a rabbit model a surgically implantable pellet releasing 5-fluorouracil (FU) and dexamethasone (DX) for 1 week and an injectable intravitreal sustained-release suspension releasing 5-FU and triamcinolone acetonide for 1 month. METHODS: Sustained-release devices and suspensions were prepared to deliver equimolar quantities of corticosteroid and 5-FU. In group 1, devices were implanted surgically into the vitreous of the right eye of 10 New Zealand White rabbits. Ten control rabbits received surgical implantation of the suture only. In group 2, drug suspension was injected into the vitreous of the right eye of 10 New Zealand White rabbits. Ten control rabbits received injection of the vehicle only. One day later, each rabbit was injected intravitreally with 250,000 homologous rabbit dermal fibroblasts. Severity of PVR was graded clinically by two masked observers on days 3, 7, 10, 14, 21, and 28. RESULTS: In group 1, clinical severity of PVR was less in the experimental group than in the control group at all time points, this was only statistically significant on day 10 (P = 0.04). Six eyes developed moderate to severe tractional RD or bullous RD in the control group by day 10 compared with none in the experimental group (P = 0.01). In group 2, the median clinical grading of eyes in the experimental group was significantly less than that in the control group at all time points through day 21 (P < or = 0.01). CONCLUSIONS: Both the intravitreal sustained-release dexamethasone-5-FU device and the triamcinolone-5-FU suspension effectively inhibit the progression of PVR in a rabbit model. Simultaneous delivery of 5-FU and corticosteroid may target different components of the wound-healing process in this disease.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×